What is the safe dose of dapagliflozin for a 72-year-old patient with an estimated glomerular filtration rate of 34 mL/min/1.73 m²?

Dapagliflozin 10 mg is SAFE and APPROPRIATE for this 72-year-old patient with eGFR 34 mL/min/1.73 m²

For cardiovascular and kidney protection (not glycemic control), dapagliflozin 10 mg once daily is the correct dose and can be safely initiated at this eGFR level. 1, 2

Key Dosing Distinctions by Indication

For Glycemic Control (Type 2 Diabetes)

• Do NOT initiate dapagliflozin if eGFR <45 mL/min/1.73 m² - it will be ineffective for glucose lowering 1, 2
• If already on therapy, may continue as eGFR declines for cardiorenal benefits

For Cardiorenal Protection (CKD, Heart Failure, CV Risk Reduction)

• Safe to initiate dapagliflozin 10 mg daily with eGFR ≥25 mL/min/1.73 m² 1, 2
• At eGFR 34, this patient falls well within the safe initiation range
• Do NOT initiate if eGFR <25 mL/min/1.73 m² 1, 2
• If eGFR drops below 25 while on therapy, may continue until dialysis 1, 2

Evidence-Based Rationale

The 2022 ADA/KDIGO consensus guidelines explicitly state that for patients with eGFR 30-44 mL/min/1.73 m² (Stage 3b CKD), dapagliflozin 10 mg daily is approved and recommended 1. The FDA label confirms initiation is appropriate down to eGFR 25 mL/min/1.73 m² for non-glycemic indications 2.

The landmark DAPA-CKD trial included patients with eGFR as low as 25 mL/min/1.73 m² and demonstrated significant benefits: 39% reduction in the composite of sustained eGFR decline ≥50%, ESKD, or renal/cardiovascular death 3. Importantly, these benefits were consistent regardless of diabetes status and across age groups, including septuagenarians 4.

Clinical Considerations at eGFR 34

Expected Initial Response

• Anticipate an acute eGFR dip of 3-5 mL/min/1.73 m² within first 2-4 weeks 5, 6
• This is reversible and expected - represents hemodynamic adjustment, not kidney injury
• After initial dip, expect slower chronic eGFR decline compared to no treatment 3, 6

Monitoring Requirements

• Check eGFR at 2-4 weeks after initiation to document expected dip
• Reassess volume status and blood pressure at follow-up
• Monitor for hypovolemia, especially if on diuretics 5

Medication Adjustments

• Reduce diuretic dose if patient is volume depleted or at risk for hypotension 5
• Adjust insulin or sulfonylureas if used for diabetes to prevent hypoglycemia (though glucose-lowering effect minimal at this eGFR) 1
• Maintain at least low-dose insulin if patient is insulin-dependent to reduce DKA risk 1

Safety Precautions Specific to This Patient

Volume Status

• Assess and correct volume depletion before initiating 2
• Particularly important in elderly patients (age 72)

Sick Day Planning

• Hold dapagliflozin during acute illness with nausea, vomiting, diarrhea, or prolonged fasting 5
• Discontinue 3-4 days before major surgery 2
• Resume when clinically stable and oral intake restored

Genital Hygiene

• Counsel on daily hygiene to reduce mycotic infection risk (6% incidence vs 1% placebo) 1
• Higher risk in women; easily treated but requires awareness

Ketoacidosis Risk

• Very low risk in type 2 diabetes at this eGFR (glucose-lowering effect minimal)
• Maintain insulin if insulin-dependent
• Educate on atypical presentation (euglycemic DKA possible) 1

Contraindications to Verify

• No initiation if eGFR <25 mL/min/1.73 m² 1, 2
• History of serious hypersensitivity to dapagliflozin 2
• Type 1 diabetes (for glycemic indication) 2

Bottom Line Algorithm

At eGFR 34 mL/min/1.73 m²:

1. ✓ Safe to initiate dapagliflozin 10 mg daily for cardiorenal protection
2. ✓ Do NOT use for glycemic control (ineffective at this eGFR)
3. ✓ Assess volume status before starting
4. ✓ Expect 3-5 mL/min/1.73 m² eGFR dip in first month
5. ✓ Continue therapy even if eGFR drops to 20-24 range
6. ✓ Discontinue only at dialysis initiation or if eGFR <20 on initiation

The 2022 ADA/KDIGO guidelines provide the strongest evidence that dapagliflozin 10 mg daily is both safe and beneficial at eGFR 34, with proven mortality and kidney protection benefits that outweigh risks in this population 1.